Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Folks 253 is the distance between London and Barnard Castle, my satirical jest was based on this,
I did warn about the Msrsden interview effect on the SP
He wants it down for his last top up !!
Boris, "Should we start heading north"?
Dominic "Yes !! , Boris bring the car round we're heading North after you deliver my speech, the roads are quieter after lockdown'
" Boris, but Dominic its 253 miles", oh I thought that was SNG share price
Quite surprised that after RM’s interview it didn’t head up a little today...
I'm suprised this is not in positive territory
News over the week end would not suprise me.
Brighty.......agree, also an NCYT holder and still holding and it will push on. What I don't get is the Finncap update where they say EUA approval after phase 3 in Q2. That's April onwards........Is that how others here interpret it ? If that's the case what's going to push the SP here in the next 1/2 months ?
or you could go with the numis £50 one :)
If you look at NCYT, which I still hold, and its share price it is pretty clear what is going to happen here soon. We are about 3 months behind the NCYT stratospheric rise. They did their raise and then the real news flow began. On Sept 1st NCYT was 300p. It is now 1030p. This x 3 gain has happened within 2 months. I predict that this is what is going to happen here, where we will see a similar x 3 rise to 550p following a number of RNS'. We know the science works and winter flu is about to add to the covid picture. The raise is out of the way and once the 175p shares are cleared in the next few weeks we are up and running for our next big rise. Good luck, Brighty
Is this a new broker note? What's the price target?
Are they saying EUA approval after Phase 3 ( ie Q2 2021 ) ???
For those who missed this report.
House broker finnCap has raised its price target on Synairgen PLC to 420p (LON:SNG) following its fundraise and managed access programme with Clinigen. Synairgen this week raised £80mln to fund a Phase III trial for its candidate SNG001 in COVID-19 disease, which is due to commence in this quarter. The trial will be run globally by Parexel with results expected in second-quarter 2021. The £80mln raised has also been earmarked to scale up manufacturing said the broker. The trial follows a successful pre-IND meeting with the FDA, which provided the guidance to commence such a study, added finnCap. “Assuming that this trial replicates the results seen in the 100-patient Phase II trial, we would expect Emergency Use Approval (EUA) to follow shortly thereafter. “Meanwhile, the Managed Access Programme (MAP) in the UK and Europe, run by Clinigen, could generate early commercial revenues.” Richard Marsden, CEO, Synairgen, commented: "It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. "finnCap has always been supportive and built a good register of institutions in March which was broadened further in this funding. “Having demonstrated the great promise of SNG001 in hospitalised COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need." FinnCap added this latest round will mean it has raised a total of £94mln for Synairgen since April, including a £14m fundraise to progress its candidate into Phase II trials. The Phase II trial of hospitalised COVID-19 patients showed that SNG001 reduced odds of developing severe disease, increased likelihood of recovery and reduced breathlessness. Geoff Nash, finnCap’s Corporate Finance Director, Life Sciences added: “We are extremely proud of what Synairgen has achieved, especially over the last eight months. “We have always been strong believers in the value of SNG001 and delighted to have generated so much interest and support for this great success story of British biotech. “
The latest cash injection will allow the life sciences group to fund a phase III trial of SNG001, an inhaled interferon-beta powder. It will also allow it to ramp up production next year to 100,000 treatment courses a month.
There is lack of investors more traders taking there 10%
All stocks are doing the yo yo affect.